Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. METHODS: This is an open-label retrospective...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Castillo-Trivino, Tamara, Mowry, Ellen M., Gajofatto, Alberto, Chabas, Dorothee, Crabtree-Hartman, Elizabeth, Cree, Bruce A., Goodin, Douglas S., Green, Ari J., Okuda, Darin T., Pelletier, Daniel, Zamvil, Scott S., Vittinghoff, Eric, Waubant, Emmanuelle
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2011
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033401/
https://ncbi.nlm.nih.gov/pubmed/21304907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0016664
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki